Data on clinical manifestations and outcome of hepatic sarcoidosis are scarce. This study aimed to use a population-based cohort of patients with incident sarcoidosis to better describe the characteristics of hepatic sarcoidosis.
INTRODUCTION
Sarcoidosis is a chronic granulomatous infl ammatory disease of unclear etiology. Th e characteristic histological fi nding of sarcoid granuloma consists of epithelioid cells and multinucleated cells without area of necrosis, unlike caseating granuloma of tuberculosis ( 1 ) . It has been estimated that 70,000-80,000 new cases of sarcoidosis are diagnosed in the United States annually with a signifi cant variation across regions and ethnic groups ( 2, 3 ) .
Sarcoidosis can virtually aff ect any organ, with lung and mediastinal lymph node being the most frequently aff ected sites ( 4 ) . Liver involvement by sarcoidosis is relatively common with prevalence ranging from 5 to 30% in antemortem cohort studies (5) (6) (7) (8) (9) and as high as 70% in an autopsy study ( 10 ) . However, clinical characteristics and outcome of hepatic sarcoidosis are not well-defi ned as most available studies used referral-based cohorts which may not refl ect the disease as it occurs in the community. Th is study aimed
METHODS

Participants and study design
Th is is a retrospective cohort study that utilized the medical record-linkage system of the Rochester Epidemiology Project to identify potential cases of sarcoidosis from 1976 to 2013 using diagnosis codes related to sarcoid, sarcoidosis, and non-caseating granuloma. Th e Rochester Epidemiology Project medical recordlinkage system provides comprehensive access to medical records of all residents of Olmsted County, MN, USA, from all local healthcare providers, which include the Mayo Clinic, the Olmsted Medical Center and their affi liated hospitals, local nursing homes, and the few private practitioners. Th is approach allows identifi cation of virtually all clinically recognized cases of sarcoidosis in the community. Detailed methodology and clinical application of the Rochester Epidemiology Project medical record-linkage system has previously been described ( 12 ) .
Medical records of those potential cases with sarcoidosis related diagnostic codes were individually reviewed. Th e diagnosis of sarcoidosis required a diagnosis made by physicians who evaluated the patient supported by the presence of non-caseating granuloma on histopathology, radiologic features of intrathoracic sarcoidosis, compatible clinical presentation, and exclusion of other granulomatous diseases such as tuberculosis and fungal infection. Th e only exception to the requirement of histopathological confi rmation was stage I pulmonary sarcoidosis that required only the presence of symmetric bilateral hilar adenopathy on chest X-ray or computerized tomography without any other identifi able causes. Isolated granulomatous disease of a specifi c organ without intrathoracic sarcoidosis was also included if other possible causes of granulomatous infl ammation were excluded. Prevalent cases (i.e., cases with sarcoidosis before residency in Olmsted County) were not included.
Confi rmed cases of sarcoidosis were then reviewed for liver involvement. If the patient had systemic sarcoidosis (pulmonary sarcoidosis with or without involvement of other organs), liver involvement by sarcoidosis was defi ned as the presence of hypodense nodular lesions on liver imaging study or the presence of abnormal liver biochemical tests without other identifi able causes (such as drugs, viral hepatitis, autoimmune liver diseases, fatty liver, and signifi cant alcohol consumption). Histopathological confi rmation was not necessary in this situation. However, if the patient did not have systemic sarcoidosis, diagnosis of isolated hepatic sarcoidosis required the presence of non-caseating granuloma on biopsy and exclusion of other causes of granulomatous hepatitis (such as tuberculosis, brucellosis, drugs, and primary biliary cirrhosis).
Data on demographic characteristics, clinical manifestations related to hepatic sarcoidosis, imaging study of the liver, liver biochemical tests at baseline, as well as at last follow-up visit, treatment and outcome were collected. Follow-up was continued until death, migration out of system, or 1 February 2017. Th is study was approved by the Mayo Clinic and the Olmsted Medical Center Institutional Review Boards. Th e study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as refl ected in a priori approval by the institution's human research committee. Th e need for inform consent was waived.
Statistical analysis
Descriptive statistics (percentages, means, and so on) were used to summarize the characteristics of the cohort. Th e cumulative incidence of cirrhosis adjusted for the competing risk of death was estimated ( 13 ) . Th ese methods are similar to the KaplanMeier method with censoring of patients who are still alive at last follow-up. However, patients who died before experiencing cirrhosis are appropriately accounted for to avoid overestimation of the rate of occurrence of the events of interest, which can occur if such subjects are simply censored at death. Mortality rates were estimated using the Kaplan-Meier method and compared with expected mortality for persons of the same age, sex, and calendar year estimated using Minnesota population life tables. Th e standardized mortality rate was estimated as the ratio of the observed and expected number of deaths. Standardized mortality rate 95% confi dence intervals were calculated assuming that the expected rates are fi xed and the observed rates followed a Poisson distribution. A Cox model including the entire sarcoidosis cohort with liver involvement modeled as a time-dependent covariate was used to examine whether liver involvement was a prognostic factor for death among patients with sarcoidosis aft er adjustment for age, sex, and calendar year of sarcoidosis diagnosis. A P -value of <0.05 was considered statistically signifi cant for all analyses. Analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA) and R 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Baseline characteristics
Out of 345 incidental cases of sarcoidosis, 19 cases (6%) had liver involvement (mean age 46.1 years, 53% female and 79% Caucasian). Median time from sarcoidosis diagnosis to hepatic involvement was 0.0 months (range: −3.3, 78.5 months). Median length of follow-up from diagnosis of hepatic sarcoidosis to last follow-up was 10.1 years (range: 0.0, 20.9 years). Most patients were asymptomatic from liver disease. Liver involvement was discovered in evaluation of abnormal biochemical tests/imaging study (12 cases; 63%) or at autopsy (3 cases; 16%). Most patients were diagnosed on the basis of positive liver biopsy and cholestatic biochemical liver tests (seven cases) followed by positive imaging study and cholestatic biochemical liver tests (four cases); positive imaging study, liver biopsy, and cholestatic biochemical liver tests (four cases); and positive liver biopsy alone (three cases) and positive imaging study alone (one case). Most cases of hepatic sarcoidosis occurred in conjunction with pulmonary sarcoidosis (16 cases). Only three cases had hepatic sarcoidosis in isolation without intra-thoracic disease. At diagnosis of liver disease, alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) were elevated in the majority of patients (15 of 17 tested patients (88%) and 9 of 10 tested patients (90%), respectively). Th e mean of ALP was 394.6 international units (IUs) l −1 (upper normal limit 118 IU l −1 (UNL); 3.3 times UNL) and the mean of GGT was 175.1 IU l −1 (UNL 29 IU l −1 ; 6.0 times UNL). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were elevated in 10 patients (71% of tested patients) and 9 patients (53% of tested patients), respectively. Th e mean of ALT was 68.3 IU l −1 (UNL 45 IU l −1 ; 1.5 times UNL) and the mean of AST was 50.9 IU l −1 (UNL 43 IU l −1 ; 1.2 times UNL). Hyperbilirubinemia was seen in only two patients (10%). Mean albumin was 4.0 g dl −1 . No prolongation of prothrombin time test was observed.
Imaging studies (ultrasonography or computerized tomography of the liver) were obtained at diagnosis of hepatic sarcoidosis in 16 patients. It was normal in nearly half ( 9 ) of the cases. Th e most common radiographic abnormality was hypodense nodular lesions (six patients) followed by hepatomegaly (three patients).
Liver biopsy was performed in 16 patients; non-caseating granulomas were identifi ed in 14 cases (88%).
Anti-mitochondrial antibody, anti-smooth muscle antibody, anti-liver kidney microsome type 1, and anti-neutrophil cytoplasmic antibody were obtained in 10, 7, 3, and 5 patients, respectively. None of these tests were positive. Anti-nuclear antibody was tested in 10 patients and was present in 4 cases (40%). Angiotensinconverting enzyme was tested in 15 patients and was elevated in 9 of them (60%). Baseline characteristics, liver biochemical tests, pathology, and imaging study of patients in this cohort are summarized in Table 1 .
Treatment
Oral glucocorticoids were the most commonly used medications in management of the hepatic disease. A total of 11 patients with hepatic sarcoidosis were exposed to oral glucocorticoids at some point during follow-up, which corresponded to an estimated 30-year cumulative incidence of ever using this medication of 66.5% (95% confi dence interval (CI),32.5-83.4). A small portion of patients were exposed to non-biologic immunosuppressive agents. Two patients received methotrexate, corresponding to an estimated 30-year cumulative incidence of 12.5% (95% CI, 0.0-27.3). One patient was treated with hydroxychloroquine (estimated 30-year cumulative incidence 6.2% (95% CI, 0.0-17.4)) and one patient was treated with a tumor necrosis factor alpha inhibitor (estimated 30-year cumulative incidence 6.7% (0.0-18.5)).
Outcome
A total of four patients in this cohort developed liver cirrhosis. Cirrhosis was found at diagnosis of hepatic sarcoidosis in two patients, whereas the other two patients developed cirrhosis during follow-up (one at 1 year and one at 12 years aft er diagnosis of hepatic sarcoidosis). All patients with cirrhosis had radiographic evidence of cirrhosis. Histopathological confi rmation was performed in two patients. Signs and symptoms of portal hypertension (including ascites and esophageal varices) were observed in three of these four patients with cirrhosis. No case of portal hypertension without cirrhosis was observed. None of the patients in this cohort developed hepatocellular carcinoma or underwent liver transplantation.
Improvement of liver biochemical tests was observed. Mean of ALT, AST, and ALP at the last test were lower compared with the values at diagnosis with the mean of 49.9 IU l −1 (1.1 times UNL), 36.8 IU l −1 (0.86 times UNL), and 148.6 IU l −1 (1.26 times UNL), respectively (data on GGT are not available, as only 1 patient had GGT aft er the initial diagnosis). Of those 10 patients who had elevated ALT at diagnosis, 6 patients had normalized ALT at the last follow-up, 2 had lower ALT but not to the normal range, and 2 did not have any follow-up ALT. Of those nine patients who had elevated AST at diagnosis, four patients had normalized AST at the last follow-up, four had lower AST at the last follow-up but not to the normal range, and one did not have any follow-up AST. Normalization of ALP occurred in 8 of 15 patients with elevated ALP at diagnosis, 5 had lower ALP at the last follow-up but not to the normal range, 1 had slightly higher ALP, and 1 did not have any follow-up ALP.
Oral glucocorticoids were used to treat 11 of the 16 patients whose hepatic sarcoidosis was not found at autopsy and several were also treated with antimetabolite immunosuppressive agents. Th e ALP was elevated at diagnosis in 10 of the glucocorticoidtreated patients. At the last follow-up, six patients had normalized ALP, whereas three patients had lower ALP but not to the normal range. Follow-up ALP was not available for one patient. All of the fi ve patients who did not receive treatment with oral glucocorticoids or immunosuppressive agents had elevated ALP at diagnosis. At last follow-up, two of these patients had normalized ALP, two patients had lower ALP but not to the normal range, and one patient had a higher ALP. Decisions regarding treatment with oral glucocorticoids and immunosuppressive agents were primarily guided by the severity and activity of non-hepatic sarcoidosis in more than half of patients (7 of 11). Clinical characteristics, laboratory investigations, and clinical outcomes of individual patients are provided in Table 2 .
Follow-up imaging was obtained in all six patients with hypodense nodular lesions in the liver and resolution of the hepatic nodules was observed in all but one patient.
Of 17 patients whose diagnosis of hepatic sarcoidosis were not made at autopsy, 3 died during follow-up (standardized mortality ratio of 2.05 (95% CI, 0.42-6.00, P =0.20)). Liver involvement was a signifi cant prognostic factor for death among patients with sarcoidosis in this cohort, with hazard ratio of 5.79 (95% CI, 2.05-16.36, P <0.001 adjusted for age, sex, and calendar year of sarcoidosis diagnosis).
DISCUSSION
Th is is the fi rst population-based study using comprehensive individual medical record review to describe the epidemiology, clinical characteristics, and outcome of hepatic sarcoidosis. Compared with previous referral-based cohort studies ( 5-9 ) that reported a prevalence of hepatic involvement by sarcoidosis between 5 and 30%, the prevalence in this cohort was at the lower range. Th e lower frequency probably refl ects the population-based nature of the study that may capture a more complete spectrum of sarcoidosis, including those with milder disease without extensive extrathoracic involvement, unlike referral-based cohorts that may overestimate the prevalence of patients with more severe disease as a result of referral bias. Nonetheless, a post-mortem study from Japan found that 70% of patients with sarcoidosis had evidence of hepatic involvement at autopsy ( 10 ), which is considerably higher than the prevalence from ante-mortem cohorts, suggesting that liver involvement by sarcoidosis is generally under-recognized in clinical practice. Th e relatively symptomless nature of hepatic sarcoidosis could be responsible for this discrepancy in prevalence estimates of hepatic involvement. Th e majority of patients in the current study cohort did not have any symptoms from their liver disease, similar to other studies that observed symptoms in only 25-40% of patients ( 14, 15 ) . Only four patients in this study (20%) had abdominal pain and only two patients (10%) were found to have hepatomegaly on physical examination. No patient presented with cholestatic symptoms (pruritus and/or jaundice). Th us, most cases of hepatic sarcoidosis are identifi ed based upon evaluation of liver biochemical tests and imaging studies, which are generally the crucial fi rst step in recognizing and diagnosing hepatic sarcoidosis. Whether routine screening for hepatic involvement in patients with sarcoidosis using liver biochemical tests and/or imaging study should be recommended requires further investigation for cost-eff ectiveness analysis.
Ethnic background may also have a signifi cant role in the lower prevalence of hepatic involvement identifi ed in this predominantly Caucasian cohort. Clinical manifestations of sarcoidosis vary across ethnic groups ( 2, 3, 16 ) . In fact, a study that prospectively recruited patients with newly diagnosed sarcoidosis from 10 centers across the United States found that hepatic involvement was ~3 times more common among African Americans than in Caucasians ( 17 ) .
Th e most commonly abnormal biochemical liver tests were elevated ALP and GGT, likely refl ecting the infi ltrative nature of sarcoidosis. On average, these tests were elevated more than three times the UNL. Elevated AST and ALT were also found, but are less frequent and less severe than ALP/GGT elevations, with means of <2 times of UNL. Th ese fi ndings suggest that other causes of hepatic injury should be explored among patients with sarcoidosis who have signifi cantly elevated serum aminotransferase with normal or minimally elevated ALP/GGT. Hyperbilirubinemia was uncommon and liver synthetic function was preserved in all patients. Th ese observations are in line with data from previous cohort ( 15, (18) (19) (20) . Angiotensin-converting enzyme was elevated in only 60% of tested patients, which suggest its poor sensitivity for diagnosis of hepatic sarcoidosis, similar to its poor performance for diagnosis of systemic sarcoidosis ( 21, 22 ) .
Only approximately half of patients had an abnormal imaging study. Th e most common abnormality in this cohort was hypodense nodular lesions (35%) followed by hepatomegaly (18%). Th e frequency of hepatic nodules varies considerably among studies, ranging from 5 to 38%, depending on the underlying population and methodology ( 19, 20, 23, 24 ) . On the other hand, liver biopsy fi ndings of non-caseating granuloma, detected in 14 out of 16 biopsies (88%), have higher sensitivity for the diagnosis of hepatic sarcoidosis. Th e high sensitivity of liver biopsy has been consistently demonstrated in several cohorts ( 14, 15, 18 ) . Th erefore, negative imaging study does not exclude hepatic sarcoidosis and liver biopsy should be performed if the clinical suspicion remains high.
At diagnosis of hepatic sarcoidosis, two patients (10%) were also found to have cirrhosis. Th is frequency is similar to previous studies that reported the prevalence of cirrhosis at diagnosis of hepatic sarcoidosis of 6-24% ( 9, 14, 15, 20 ) . Th is observation underscores the relatively symptomless nature of hepatic sarcoidosis, and that the disease may not be recognized until organ failure or death occur.
Medical treatment is generally reserved for patients with more severe disease and observation is usually recommended for patients with only mildly elevated liver enzymes ( 25, 26 ) . Th is approach is partially based on the fact that there is no randomized controlled study to confi rm the effi cacy and long-term benefi t of glucocorticoids and/or other immunosuppressive agents for treatment of hepatic sarcoidosis. Glucocorticoids are generally considered as the fi rst-line therapy (and were the most commonly used medications in this cohort) based on low-quality data from retrospective studies, which were at risk of selection bias ( 9, 26, 27 ) . Interestingly, more than half of patients in this cohort received glucocorticoid therapy, refl ecting the practice pattern of healthcare providers in this community.
Th e major strength of this study is the population-based design that refl ects the true spectrum of the disease in the community with minimal selection bias, unlike hospital-based cohorts. Th e diagnosis of both sarcoidosis and cirrhosis was verifi ed by individual medical record review, which minimized the likelihood of disease misclassifi cation. Th e long duration of follow-up allows capture of events of interest occurring during long-term follow-up. Th is is of particular importance for study of hepatic sarcoidosis, as the outcome of interest (cirrhosis) could happen years aft er the diagnosis.
Th e major study limitations are inherent to the retrospective design. Clinical information was not obtained and recorded according to a defi ned protocol. Th us, some of the pertinent data were not available. Liver imaging study and biochemical tests were obtained at physician discretion without a standard protocol, which could introduce elements of surveillance and selection bias. Generalizability of the observations to other populations may be limited as clinical manifestation of sarcoidosis varies among ethnic groups ( 2, 3 ) and the population of Olmsted County, as well is predominately of Northern European ancestry. In addition, Olmsted County has a higher proportion of workers in the healthcare industry, which may result in a diff erent pattern of hepatic sarcoidosis detection, as patients may have better access to healthcare service.
CONCLUSION
Involvement of the liver by sarcoidosis was seen in 6% of patients with sarcoidosis in this cohort. Th e majority of them were
